# US 2012/0231455 A1 · Peptide nucleic acid probes, kit and method for detecting helicobacter pylori and/or clarithromycin resistance profile and applications

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2012/0231455 A1
- Document ID: US20120231455A1
- Status: Published application
- Kind: A1
- Application number: 13/395,618
- Filed: 2010-09-13
- Published: 2012-09-13
- Earliest claimed: 2009-09-11
- Assignees: Universidade Do Minho
- Inventors: Nuno Filipe Ribeiro Pinto De Olivera Azevedo; Laura Isabel Maciera Cerqueira; Nuno Ricardo Torres Faria; Maria João Lopes Da Costa Vieira
- Web page: https://patentgrep.com/patent/US20120231455A1

## CPC

- C12Q 1/689: for bacteria
- C12Q 2600/156: Polymorphic or mutational markers
- C12Q: MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS (immunoassay G01N33/53); COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES

## Abstract

Four peptide nucleic acid probes (PNA) are for the detection of Helicobacter pylori and/or response analysis of Helicobacter pylori strains to clarithromycin. The probes are based in molecular biology methods, namely fluorescence in situ hybridization (FISH) that are used in H. pylori clarithromycin susceptibility diagnosis in several sample types, including clinical isolates and biopsies. Due to physical and chemical characteristics inherent in its structure, the probes allow a faster and more sensitive hybridization. A kit may use one or several probes described here and the related process of detection or quantification. The kit identifies H. pylori and its response to clarithromycin in clinical samples.

## Claims

### Claim 1

PNA probe for detecting the presence of Helicobacter pylori strains, or detection of Helicobacter pylori response to clarithromycin, or detection of Helicobacter pylori and its response to clarithromycin, which comprises at least one of the nucleotide sequences at least 86% structurally similar to SEQ ID Nos. 1-4.

### Claim 2 (depends on 1)

PNA probe, in accordance with claim 1, capable of detecting the target sequence in rRNA, rDNA or in Helicobacter pylori complementary rRNA sequences.

### Claim 3 (depends on 1)

PNA probe, in accordance with claim 1, capable of detecting clarithromycin resistance when comprising at least one of nucleotide sequences at least 86% structurally similar to SEQ ID Nos. 1-3.

### Claim 4 (depends on 1)

PNA probe, in accordance with claim 1, capable of detecting clarithromycin susceptibility when comprising at least one of nucleotide sequences at least 86% structurally similar to SEQ ID Nos. 4.

### Claim 5 (depends on 1)

PNA probe, in accordance with claim 1, wherein the probe is connected at least to one detectable fraction.

### Claim 6 (depends on 5)

PNA probe, in accordance with claim 5, wherein the type of detectable fraction of the probe is selected from the following groups: a conjugate, a branched detection system, a chromophore, a fluorophore, radioisotope, an enzyme, a hapten or a luminescent compound.

### Claim 7 (depends on 6)

PNA probe, in accordance with claim 6, wherein the fluorophore group is at least one of the following: fluorophores Alexa series, Alexa Fluor series, cyanine, 5- (and -6) Carboxy-2′,7′-dichlorofluorescein , the 5-ROX (5-carboxy-X-rhodamine, triethylammonium salt).

### Claim 8 (depends on 1)

Kit for detecting the presence of Helicobacter pylori strains, or detection of Helicobacter pylori response to clarithromycin, or detection of Helicobacter pylori and its response of Helicobacter pylori to clarithromycin in biological samples comprising at least one of the probes described in claim 1.

### Claim 9 (depends on 8)

Kit, according to claim 8, comprising at least one of the following solutions: one fixation solution, one hybridization solution and one washing solution.

### Claim 10 (depends on 8)

Kit, according to claim 8, wherein the fixation solution comprises 2-8% (wt/vol) of paraformaldehyde and 25-75% (vol/vol) of ethanol.

### Claim 11 (depends on 9)

Kit, according to claim 9, wherein the hybridization solution comprises formamide.

### Claim 12 (depends on 1)

A method for detection of Helicobacter pylori, or detection of H. pylori clarithromycin response or detection of H. pylori and response of Helicobacter pylori to clarithromycin in biological samples, comprising the use of at least one of the PNA probes described in claim 1 for comprising the following steps:
a. PNA probe contacting the referred samples;
b. PNA probe hybridizing the target sequence of microorganisms present in the referred samples;
c. Hybridization detecting as indicative of the referred detection and measuring of the referred samples.

### Claim 13 (depends on 10)

Method, according to claim 10, wherein the biological sample is derived from blood, air, food, water, biopsies or gastric biopsies.

### Claim 14 (depends on 12)

Method, according to claim 12, wherein the hybridization occurred by fluorescence.

### Claim 15 (depends on 1)

A method of using PNA probes of claim 1, comprising applying in a methodology for detecting Helicobacter pylori, or in detection of Helicobacter pylori clarithromycin response, or detection of Helicobacter pylori and response of Helicobacter pylori to clarithromycin in biological samples.

### Claim 16 (depends on 8)

A method of using the kit of claim 8, to be applied on detecting Helicobacter pylori, or in detection of Helicobacter pylori clarithromycin response, or detection of Helicobacter pylori and response of Helicobacter pylori to clarithromycin in biological samples.

### Claim 17 (depends on 12)

The method according to claim 12, to be applied on detecting Helicobacter pylori, or in detection of Helicobacter pylori clarithromycin response, or detection of Helicobacter pylori and response of Helicobacter pylori to clarithromycin in biological samples.
